{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:53:23Z","timestamp":1794725603554,"version":"4.9.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bone.2020.115574","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T21:20:09Z","timestamp":1596835209000},"page":"115574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis"],"prefix":"10.1016","volume":"140","author":[{"given":"Kosuke","family":"Ebina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kashii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kaneshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Miyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Kunugiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gensuke","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Etani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Goshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115574_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115574_bb0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115574_bb0015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/14656566.2016.1176147","article-title":"Treatment needs and current options for postmenopausal osteoporosis","volume":"17","author":"Gennari","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bone.2020.115574_bb0020","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/jbmr.1853","article-title":"Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene","volume":"28","author":"Cosman","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115574_bb0025","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115574_bb0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115574_bb0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00774-019-01057-1","article-title":"Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial","volume":"38","author":"Takada","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2020.115574_bb0040","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115574_bb0045","doi-asserted-by":"crossref","first-page":"100288","DOI":"10.1016\/j.bonr.2020.100288","article-title":"Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report","volume":"13","author":"Kashii","year":"2020","journal-title":"Bone Rep"},{"key":"10.1016\/j.bone.2020.115574_bb0050","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115574_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","article-title":"Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary","volume":"7","author":"Orimo","year":"2012","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2020.115574_bb0060","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00198-018-4492-y","article-title":"Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naive rheumatoid arthritis","volume":"29","author":"Ebina","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115574_bb0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","article-title":"Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance","volume":"19","author":"Lewiecki","year":"2016","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2020.115574_bb0070","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s00198-014-2819-x","article-title":"Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients","volume":"25","author":"Ebina","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115574_bb0075","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115574_bb0080","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bone.2020.115574_bb0085","first-page":"53","article-title":"PTH and interactions with bisphosphonates","volume":"1","author":"Gasser","year":"2000","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bone.2020.115574_bb0090","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115574_bb0095","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115574_bb0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220303549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220303549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:40:24Z","timestamp":1762659624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220303549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":20,"alternative-id":["S8756328220303549"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115574","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115574"}}